Sanofi’s Tzield Just Opened a Market That Didn’t Exist Last Week
Tzield's FDA approval for stage 3 type 1 diabetes creates a new disease-modifying therapy category for 2.1M U.S. patients...
Disease-Modifying Therapy
Tzield’s Stage 3 Approval Signals the End of Insulin’s Monopoly on Type 1 Diabetes
Sanofi's Tzield just won FDA approval for stage 3 T1D, threatening insulin's 68% grip on a $28.6B market and...